Cardiac Ablation Market

Market Overview

The global cardiac ablation market size was valued at USD 1.13 billion in 2022. It is estimated to reach USD 3.26 billion by 2031, growing at a CAGR of 12.3% during the forecast period (2023–2031). The cardiac ablation market growth is driven by increased cardiac arrhythmia cases and a need for minimally invasive techniques.

Cardiac ablation is a medical treatment for arrhythmias or irregular heartbeats. Arrhythmias are heart electrical abnormalities that can cause the heart to beat excessively quickly (tachycardia), too slowly (bradycardia), or irregularly. Cardiac ablation is frequently advised when drugs and other therapies fail to regulate or eliminate these irregular heart rhythms.

A growing senior population combined with an increasing population base of cardiovascular disease patients, technological advancements in the field of ablation devices, and growing awareness about the benefits of cardiac ablation procedures over conventional therapeutic and surgical procedures all contribute to the global cardiac ablation market share. However, substantial cost-cutting efforts implemented by various governments, as well as ongoing healthcare reforms in the United States, are some of the key factors impeding market growth.

Market Dynamics

Market Drivers

Increasing Prevalence of Cardiac Arrhythmias

The rising prevalence of cardiac arrhythmias such as atrial fibrillation, atrial flutter, and ventricular tachycardia has increased demand for cardiac ablation operations. As the world's population ages and lifestyle factors lead to cardiac disease, the number of people suffering from arrhythmias rises. Cardiovascular illnesses, particularly arrhythmias, are the largest cause of death worldwide, according to the World Health Organization (WHO). Arrhythmias, notably atrial fibrillation (AF), the most prevalent type of arrhythmia, are being detected in an increasing number of people. Furthermore, according to data from the American Heart Association (AHA), an anticipated 12.1 million persons in the United States will develop AF by 2030, up from 5.2 million in 2010. AF is significantly connected with aging, and the prevalence of AF is projected to rise as the population ages.

In addition, the aging global population is considerably contributing to the rising occurrence of arrhythmias. Arrhythmias are more common in older people due to cardiac muscle wear and tear, scarring, and other age-related changes. According to the European Heart Rhythm Association (EHRA), the prevalence of AF in Europe is anticipated to quadruple in the next 50 years as the European population ages. The demand for cardiac ablation procedures is directly affected by this demographic trend. Demographic developments, such as aging populations and lifestyle considerations, drive the Cardiac Ablation market trend.

Market Restraints

High Procedure Cost

Cardiac ablation operations can be costly, and the costs are not always reimbursed by insurance, posing financial challenges for patients. The high cost of ablation technology and the necessity for specialist facilities can provide financial difficulties for healthcare providers. Radiofrequency ablation employs heat radiation and is typically less expensive than other techniques, such as cryoablation. The cost can also vary depending on the ailment being treated. For example, the cost of atrial fibrillation (AF) ablation may differ from that of ventricular tachycardia (VT) ablation.

The cost of cardiac ablation procedures varies greatly depending on the country or area. Because of disparities in healthcare systems and medical technology, the cost of ablation procedures in the United States, for example, tends to be greater than in many other nations. Furthermore, high procedure costs can cause economic inequities in access to cardiac ablation since patients with little financial resources may not have equitable access to this modern therapy option.

Market Opportunity

Ongoing Technological Innovation

Technological advancements in ablation devices, 3D mapping systems, and real-time monitoring tools enable more precise and successful cardiac ablation procedures. Catheter ablation technology advancements have resulted in more effective and safer operations. For example, the invention of contact force sensing catheters enables electrophysiologists to precisely detect the contact between the catheter tip and heart tissue during ablation, optimizing lesion production.

Furthermore, sophisticated 3D mapping technologies like Biosense Webster's CARTO 3 System provide high-resolution, real-time heart mapping. This technology allows electrophysiologists to visualize the heart's electrical activity, plan ablations more precisely, and shorten surgery timeframes.

These technical improvements in the cardiac ablation market improve operation effectiveness and patient safety, shorten procedure times, and improve patient outcomes. Healthcare providers and device makers can use these improvements to give cutting-edge treatment options, attract patients looking for the newest medical technology, and contribute to the growth of the cardiac ablation market.

Regional Analysis

The global cardiac ablation market analysis is conducted in North America, Europe, Asia-Pacific, the Middle East and Africa, and Latin America.

North America Dominates the Global Market

North America is the most significant global cardiac ablation market shareholder. The presence of a significant number of ablation facilities, a rising installation base of advanced cardiac ablation catheters, an increase in demand for minimally invasive cardiac treatment procedures, and continuing projects will all contribute to the growth of the market in North America. Aside from that, the United States has an improved healthcare infrastructure that allows it to give adequate treatment to patients throughout the region. With major players such as Johnson & Johnson, Abbott, and Boston Scientific Corporation, North America will likely grab a significant proportion of the worldwide cardiac ablation technologies market. The cheap availability of cutting-edge technology underpins these businesses' growth efforts, assisting them in building a diverse product offering. Effective product positioning and technological developments assist these firms in obtaining money from other locations. Broward Health Medical Centre, for example, is launching a robotic electrophysiology (EP) program to increase access to advanced minimally invasive treatment of heart rhythm abnormalities in Florida.

Aside from the efforts of these industry leaders, the demand for cardiac ablation devices is very high in the United States due to many patients suffering from heart diseases. According to numerous studies, cardiac arrest is the top cause of mortality in the United States. This makes the country an important cardiac ablation technologies market, granting North America a dominant position.

Asia-Pacific is anticipated to exhibit a healthy CAGR over the forecast period due to the exponential development in healthcare spending and available facilities across economies. Significant investments from important regional companies would help to accelerate the growth rate of the cardiac ablation technology market, owing to lower production costs in India and China. The ablation technology market had substantial growth opportunities in the region. The market is expected to thrive throughout the projected period, owing to the rising incidence and prevalence of cancer and cardiac disorders and technological advancements in ablation products and technology.

Furthermore, the World Heart Federation emphasizes cardiovascular disease as a leading cause of death in the Southeast Asian region, emphasizing the terrible toll caused by risk factors such as air pollution, hypertension, and poor diets. This scenario accounts for almost one-third of all fatalities annually, with air pollution alone accounting for 17% of all mortalities and 28% of cardiovascular disease-related deaths.

In Europe, the market for cardiac ablation is expected to develop steadily over the projected period, owing to rising knowledge of new treatment alternatives and their rapid acceptance. Complementary government initiatives and coordinated efforts by businesses to provide cost-effective medicines contribute considerably to the regional market's growth. In October 2021, Biosense Webster announced the successful implementation of a radiofrequency balloon ablation catheter across European sites, demonstrating the region's consistent advancement in catheter-based cardiac electrophysiology (EP) mapping and ablation.

Segmental Analysis

The global cardiac ablation market is segmented based on technology, application, and region.

By Technology, the market is further segmented into Radiofrequency (RF), Electrical Ablation, Cryoablation, Ultrasound Ablation, and Microwave Ablation.

Radiofrequency (RF) Ablation segment holds the largest share of the market. high-frequency electrical energy is used in RF ablation to generate heat and destroy the targeted tissue in the heart that is causing aberrant electrical impulses. Atrial fibrillation and other supraventricular arrhythmias are often treated with RF ablation. The rising incidence of cardiovascular disorders drives demand for this segment. Furthermore, the growing elderly population worldwide will contribute to the RF ablation technique's market expansion.

Electrical ablation, also known as direct current (DC) ablation, is a procedure that employs electrical energy to generate lesions or scar tissue in the heart. It is now used less frequently and has mostly been supplanted by other ablation procedures, such as RF ablation.

The market can be bifurcated by application into Cardiac Rhythm Management and Open Surgery.

Cardiac Rhythm Management segment generates the most revenue in the market. cardiac rhythm management treats cardiac arrhythmias, or abnormal heartbeats, through cardiac ablation procedures. Atrial fibrillation, atrial flutter, supraventricular tachycardia, ventricular tachycardia, and other rhythm abnormalities are examples of arrhythmias. In cardiac rhythm treatment, the primary goal of cardiac ablation is to restore normal heart rhythm, relieve symptoms, and lower the risk of catastrophic consequences associated with arrhythmias. Furthermore, atrial fibrillation and flutter patients require adequate cardiac rhythm care. 

Traditional surgical treatments that entail creating an incision in the chest or the heart to access and treat cardiac problems are called open surgery. Cardiac ablation may be utilized in open-heart surgery, such as a maze or Cox-Maze operations.

Recent Developments

• April 2023- AngioDynamics and Cardiva expand their partnership to reach more European patients with Life-Saving Products.
• May 2023- The global clinical trial results of the Medtronic Extravascular ICD reaffirmed the device's safety and effectiveness.
• September 2023- The FDA approved the latest-generation WATCHMAN FLXTM Pro Left Atrial Appendage Closure Device from Boston Scientific.